The simulation hypothesis—the idea that our universe might be an artificial construct running on some advanced alien computer ...

Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...

The surface of Earth is finite. We can measure it. If it was expanding, then its size would grow with time. And once again, good ol' Earth helps us understand what the universe might be doing beyond ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

After four years of regularly introducing news maps, gameplay modes, and equipment for Halo Infinite, Halo Studios has announced that it is releasing the last major update for the game on Nov. 18.

This month’s content update for Halo Infinite is its last, as the team focuses on ‘multiple’ Halo titles in development. This month’s content update for Halo Infinite is its last, as the team focuses ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...